A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer

University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, 600 Highland Avenue, K6/534 CSC, Madison, WI 53792, USA.
Investigational New Drugs (Impact Factor: 2.92). 09/2009; 29(1):118-25. DOI: 10.1007/s10637-009-9318-5
Source: PubMed


To assess the maximum well-tolerated dose (MWTD), dose limiting toxicity (DLT), pharmacokinetics (PK) and pharmacodynamics of zibotentan, a novel specific endothelin-A receptor antagonist, in patients with metastatic prostate cancer.
Patients with metastatic, castrate-resistant prostate cancer (CRPC) were treated with escalating doses of oral zibotentan (ZD4054) 10-200 mg once daily. The initial cohort received 28 daily doses (Period 1). Patients who had evidence of clinical benefit and who had not met any of the criteria for withdrawal were allowed to receive zibotentan at their current dose level until they no longer derived clinical benefit (Period 2). PK of zibotentan and changes in prostate-specific antigen and bone markers were also assessed.
Sixteen patients were evaluable for the safety and single-dose PK analyses. Eleven patients completed Period 1, and nine patients proceeded to Period 2. DLTs were encountered at 22.5 mg; one patient had grade 3 dyspnea and peripheral edema and a second patient had grade 3 headache and intraventricular hemorrhage. Enrollment was expanded at the 15 mg dose level to further determine the safety and tolerability of zibotentan. No DLTs were seen at 15 mg, and the most frequent adverse events were headache, peripheral edema, fatigue, nasal congestion and nausea.
The MWTD for zibotentan was 15 mg orally daily. The predominant adverse events observed were consistent with those reported for this class of drugs, and prolonged stable disease was noted in some patients. Phase III studies with zibotentan in men with metastatic CRPC are ongoing.

Download full-text


Available from: Glenn Liu,
  • Source
    • "Ratios of geometric means of each hepatically impaired group compared to the normal function group (mild/moderate/severe: control) and 90% confidence intervals (CIs) were reported. An effect of hepatic impairment was predefined to have occurred if the upper 90% CI for the ratio did not lie below 2. This was chosen as zibotentan 15 mg has previously been tolerated in patients with CRPC; however, zibotentan 22.5 mg was not tolerated, therefore doubling of the zibotentan dose was to be eliminated [30]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Zibotentan (ZD4054) is a specific endothelin A (ETA) receptor antagonist being investigated for the treatment of prostate cancer. As zibotentan is eliminated by renal and metabolic routes, clearance may be reduced in patients with hepatic or renal impairment, leading to greater drug exposure. Open-label studies investigated the PK and tolerability of zibotentan in subjects with hepatic or renal impairment, compared with those with normal organ function. In the hepatic and renal studies, respectively, subjects were divided into categories using Child-Pugh classification or 24-hour urine creatinine clearance (mild, moderate, or severe impairment and normal function). Each subject received a single oral dose of zibotentan 10 mg and PK sampling was undertaken. Within the hepatic study, AUC and Cmax were expressed as the ratio of geometric means and 90% CI for each impairment group compared with the normal function group. The possibility that hepatic impairment had a clinically relevant effect on exposure was considered if the upper 90% CI for the ratio exceeded 2. In the renal study, AUC, Cmax and t1/2 were analyzed using linear regression fitting effects for creatinine clearance and age. In the hepatic and renal studies respectively, 32 subjects (eight per group) and 48 subjects received treatment (n = 18 normal, n = 12 mild, n = 9 moderate, n = 9 severe). Zibotentan Cmax was not significantly affected by hepatic or renal impairment. Compared with the normal function group, zibotentan AUC was 40% (1.40; 90% CI 0.91-2.17), 45% (1.45; 90% CI 0.94-2.24) and 190% (2.90; 90% CI 1.88-4.49) higher in subjects with mild, moderate and severe hepatic impairment, respectively, and 66% (1.66; 90% CI 1.38-1.99), 89% (1.89; 90% CI 1.50-2.39) and 117% (2.17; 90% CI 1.64-2.86) higher in subjects with mild, moderate and severe renal impairment, respectively. In both studies mean t1/2 increased and zibotentan clearance decreased with the degree of impairment. Headache was the most common AE in all groups. Zibotentan absorption was unchanged, however, exposure was higher in subjects with hepatic or renal impairment due to slower clearance. This increased exposure did not result in differences in the range or severity of AEs observed. ClinicalTrials.gov: NCT00672581 and AstraZeneca study number D4320C00016 (renal trial; conducted in Germany).
    BMC Clinical Pharmacology 03/2011; 11(1):3. DOI:10.1186/1472-6904-11-3 · 1.36 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer represents the most common cancer in men in US and the fifth in men in Korea. For the patients with advanced prostate cancer, androgen deprivation therapy (ADT) remains the gold standard. However, patients with metastatic prostate cancer treated with ADT frequently develop hormone-refractory status (HRPC). Recent large randomized clinical trials demonstrated that docetaxel-based chemotherapy enhance survival and improve the quality of life in patients with HRPC. Although docetaxel-based chemotherapy has become the standard treatment for HRPC, PSA responses rarely exceed 50% and median survival is still less than 2 years. Therefore, there is a need for newer agents that can improve outcomes. This review focuses on the current therapies for the treatment of HRPC, including new cytotoxic agents, antiproliferative agents, antitumor vaccine and antiangiogenic agents. These approaches yielded expected or disappointing results in the phase II or III trials. Interpretation of these trials is sometimes complicated by discordant radiographic and PSA responses. Further investigation in search of more predictive new markers is warranted. Docetaxel-based chemotherapy has become the first-line standard treatment for HRPC, but the survival results are not satisfactory. Therefore, newer agents are being developed with promising results in phase II trials. These new agents should demonstrate higher patient survival rate in phase III studies on a larger scale in order to be approved for clinical use.
    Journal of the Korean Medical Association 02/2010; 53(2). DOI:10.5124/jkma.2010.53.2.126 · 0.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The endothelin (ET) axis, which includes the biological functions of ETs and their receptors, has played a physiological role in normal tissue, acting as a modulator of vasomotor tone, tissue differentiation and development, cell proliferation and hormone production. Interestingly, it also functions in the growth and progression of various tumors. Several researchers have identified the blockade of the ET-1 receptor as a promising therapeutic approach. The clinical investigation of an orally bioavailable ET antagonist, atrasentan, in prostate cancer, is encouraging. In this neoplasia, it has shown antitumor activity, bone metastasis control and amelioration of cancer-related pain but improvement in time to progression and overall survival has still not been demonstrated. The clinical trials of other ET antagonists are reported. Literature research was performed by Pubmed and Pharmaprojects. A comprehensive view about the use of atrasentan in the treatment of castration-resistant prostate cancer (CRPC) is provided together with the scientific rationale based on the function of ET and its receptor in various cancer development mechanisms. Atrasentan seems to be active in CRPC, although strong scientific evidence is still to be found. Interesting clinical findings regard zibotentan.
    Expert Opinion on Emerging Drugs 03/2010; 15(1):27-40. DOI:10.1517/14728210903571667 · 3.06 Impact Factor
Show more